Search Results

Mauna Kea Technologies, inventor of Cellvizio®, the multidisciplinary platform for probe-based and needle-based confocal laser endomicroscopy, unveils its new subsidiary CellTolerance, fully dedicated to its unique program for the detection and treatment of food intolerances associated with Irritable Bowel Syndrome.

Telix Pharmaceuticals Limited and Paris-based Mauna Kea Technologies, announce an expansion of the IRiS Alliance[1] through a strategic €6.0 million investment to develop new hybrid pharmaceutical-device products through the combination of Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio® surgical endomicroscopy platform.

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance” The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers.

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced the publication of a peer-reviewed meta-analysis and of an international Delphi consensus report based on a systematic, evidence-based review of endoscopic ultrasound (EUS) guided needle-based confocal laser endomicroscopy for pancreatic cystic lesion (PCL) evaluation. The

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TAVAC) published a review on the safety and efficacy of confocal laser endomicroscopy as a diagnostic tool for the evaluation of gastrointestinal pathologies.

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation – JJDC, Inc..

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced today that it has obtained 510(k) clearance ( K193416 ) from the U.S. Food and Drug Admin

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced a publication that demonstrates how Cellvizio positively impacts the diagnostic yield and the clinical management of pancreatic cystic lesions (PCL)

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, announced a mutual decision to terminate the development and distribution agreements with Cook Medical.

Mauna Kea Technologies today announced the appointment of Molly O’Neill to the Company’s Board of Directors, effective immediately.